SOMMER HOOD: Open Payments
NPI 1053027615 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$332 in 16 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $391 · 2025 $332
Food & beverage: $332
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 3 | $54 |
| Amneal Pharmaceuticals LLC | 1 | $47 |
| Lilly USA, LLC | 2 | $43 |
| ABBVIE INC. | 2 | $34 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $32 |
| Abbott Laboratories | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Corcept Therapeutics | 1 | $22 |
| Ascendis Pharma Endocrinology Inc | 1 | $21 |
| IBSA Pharma Inc. | 1 | $19 |
Products named: UNITHROID, MOUNJARO, Ozempic, UBRELVY, JARDIANCE, FREESTYLE LIBRE 3, KEVEYIS, Korlym.
Industry payments across OK — which companies pay providers there.
